1 As a GLP-1 agonist, it mimics the physiological effects of natural GLP-1 released in the body
As part of the experiment I purposefully did NOTHING different than I always did
As a GLP-1 receptor agonist, semaglutide mimics the incretin hormone GLP-1, increasing insulin release, decreasing glucagon levels, and slowing gastric emptying
Red flags requiring immediate attention include: Unexplained weight gain while on semaglutide Severe or persistent gastrointestinal symptoms Signs of pancreatitis (severe abdominal pain radiating to the back) Symptoms of gallbladder disease (right upper quadrant pain, fever, jaundice) Signs of dehydration or kidney problems (decreased urination, dizziness) Hypoglycemia symptoms if taking insulin or sulfonylureas Depression or suicidal thoughts Symptoms of thyroid problems (neck mass, difficulty swallowing, persistent hoarseness) Pregnancy or planning pregnancy (semaglutide should be discontinued at least 2 months before a planned pregnancy) These situations require prompt medical evaluation rather than waiting for a routine follow-up appointment

Last reviewed: June 8, 2026 Last updated: June 8, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations